Duke Empirical, Inc. to Present at Medtech Insight's ``Investment In Innovation'' Conference.Business Editors/Health/Medical Writers Medtech Insight 2004 In3 San Francisco Conference SANTA CRUZ, Calif.--(BUSINESS WIRE)--May 5, 2004 Duke Empirical, Inc. will be presenting on June 8th, 2004, at Medtech Insight's prestigious "Investment In Innovation" Event, taking place June 8-9, 2004, at the Palace Hotel in San Francisco. Duke Empirical, Inc., a leading developer of emergent medical technologies, announced plans to manufacture an endovascular stent-graft endovascular stent-graft Stent graft Heart surgery A prosthetic intravascular graft placed transluminally as an alternative to invasive surgical replacement of an artery with an aneurysmal dilatation; in aneurysms of the thoracic aorta, surgical interposition of a for previously untreatable Un`treat´a`ble a. 1. Incapable of being treated; not practicable. thoracic aortic arch aortic arch n. 1. The curved portion between the ascending and descending portions of the aorta, lying behind the manubrium and giving rise to the brachiocephalic trunk, the left common carotid, and the left subclavian arteries. disease conditions, including aneurysm aneurysm (ăn`y  rĭzəm), localized dilatation of a blood vessel, particularly an artery, or the heart. (TAA TAA - Track Average Amplitude ), dissection, and rupture. The company's patented endovascular technology will allow physicians to treat a greater number of patients, as well as to reduce the high levels of mortality and morbidity associated with surgical management for these life-threatening conditions. "There are currently no alternative treatment options for over 50% of diagnosed patients who are unable to undergo surgical repair," said Robert LaDuca, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . He further stated, "While endovascular stenting has become the standard of care for treatment of diseased arteries throughout the body, the aortic arch region has been particularly challenging for device manufacturers due to difficult anatomical considerations which drive device requirements." Conventional surgical repair involves replacing the affected area with a polymer graft and requires temporarily stopping blood flow through the aorta. Left untreated, aortic dissection carries a 91% mortality rate within a one-week period from onset. Complications associated with surgical treatment include paraplegia paraplegia (pâr'əplē`jēə), paralysis of the lower part of the body, commonly affecting both legs and often internal organs below the waist. When both legs and arms are affected, the condition is called quadriplegia. and loss of organ function. By performing the graft procedure using Duke Empirical, Inc.'s endovascular technology, a stent-graft is placed across the aneurysm, dissection, or rupture without interruption of aortic aortic pertaining to or emanating from the aorta. See also aortic arch. aortic aneurysm occurs most often in dogs, where it is caused by Spirocerca lupi larvae, turkeys and primates, causing dyspnea, cyanosis and coughing. blood flow, leaving the spine and other key organs functioning throughout and after the procedure. Using a common access point for many diagnostic and therapeutic procedures, a low profile catheter delivers the stent-graft to protect diseased artery walls. Currently, there are no endovascular devices approved to treat this region of the aorta. Duke Empirical, Inc. plans to file with the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for approval to market this device in the U.S. About Duke Empirical, Inc. Duke Empirical, Inc. is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. engaged in the development, manufacturing, and marketing of medical devices since 2000. The company performs design and manufacturing activities serving industry-leading manufacturers, early stage companies, and leading physicians involved in the development of life-saving technologies. The company will be presenting its work on Aortic Arch Stent-Graft during the upcoming Medtech Insight conference in San Francisco, June 8. More information on the company, including investment opportunities, may be found at www.dukeempirical.com. About Medtech Insight Medtech Insight's "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" conferences are considered the premier forum for senior executives in the medical technology and investment community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. In addition to conferences, Medtech Insight publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the San Francisco conference or for more information on Medtech Insight, please call Scott Pantel at 949-219-0150 or 888-290-2225 toll-free in the U.S., e-mail in3@medtechinsight.com, or visit http://www.medtechinsight.com/in3-11.html. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion